These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 24758902)

  • 1. [The question and analysis about maintenance therapy in advanced non-small cell lung cancer].
    Liu X
    Zhongguo Fei Ai Za Zhi; 2014 Apr; 17(4):289-93. PubMed ID: 24758902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system.
    Zeng X; Peng L; Li J; Chen G; Tan C; Wang S; Wan X; Ouyang L; Zhao Z
    Clin Ther; 2013 Jan; 35(1):54-65. PubMed ID: 23328269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer.
    Klein R; Wielage R; Muehlenbein C; Liepa AM; Babineaux S; Lawson A; Schwartzberg L
    J Thorac Oncol; 2010 Aug; 5(8):1263-72. PubMed ID: 20581708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is chemotherapy for metastatic non-small cell lung cancer "worth it"?
    Ruckdeschel JC
    J Clin Oncol; 1990 Aug; 8(8):1293-6. PubMed ID: 2166141
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater.
    She L; Hu H; Liao M; Xia X; Shi Y; Yao L; Ding D; Zhu Y; Zeng S; Shen L; Huang J; Carbone DP
    Lung Cancer; 2019 Dec; 138():88-94. PubMed ID: 31655368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
    Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
    Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Effectiveness and Cost-effectiveness of Target Therapies for Adult Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer: A Systematic Review.
    Bearz A; Berretta M; Tirelli U
    Curr Cancer Drug Targets; 2018; 18(5):405-409. PubMed ID: 28176647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy of advanced non-small cell lung cancer.
    Jassem J
    Ann Oncol; 1999; 10 Suppl 6():77-82. PubMed ID: 10676557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pemetrexed approved for the first-line treatment of non-small-cell lung cancer: summary of the NICE appraisal.
    Vrouchou P; Kandaswamy P; George E; Barnett D
    Lancet Oncol; 2009 Nov; 10(11):1031-2. PubMed ID: 19891055
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
    Brown T; Pilkington G; Bagust A; Boland A; Oyee J; Tudur-Smith C; Blundell M; Lai M; Martin Saborido C; Greenhalgh J; Dundar Y; Dickson R
    Health Technol Assess; 2013 Jul; 17(31):1-278. PubMed ID: 23886301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany.
    Bosch-Barrera J; Gil-Bazo I
    Lung Cancer; 2011 Feb; 71(2):244; author reply 245. PubMed ID: 21055842
    [No Abstract]   [Full Text] [Related]  

  • 12. [Maintenance therapy for advanced non-small-cell lung cancer].
    Saruwatari K; Yoh K
    Gan To Kagaku Ryoho; 2014 Aug; 41(8):926-31. PubMed ID: 25132023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L).
    Seto T; Azuma K; Yamanaka T; Sugawara S; Yoshioka H; Wakuda K; Atagi S; Iwamoto Y; Hayashi H; Okamoto I; Saka H; Mitsuoka S; Fujimoto D; Nishino K; Horiike A; Daga H; Sone T; Yamamoto N; Nakagawa K; Nakanishi Y
    J Clin Oncol; 2020 Mar; 38(8):793-803. PubMed ID: 31880966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal.
    Dickson R; Bagust A; Boland A; Blundell M; Davis H; Dundar Y; Hockenhull J; Martin Saborido C; Oyee J; Ramani VS
    Pharmacoeconomics; 2011 Dec; 29(12):1051-62. PubMed ID: 21967156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
    Wu B; Chen H; Shen J; Ye M
    Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
    Brown T; Boland A; Bagust A; Oyee J; Hockenhull J; Dundar Y; Dickson R; Ramani VS; Proudlove C
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):71-9. PubMed ID: 21047494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non-Small-Cell Lung Cancer.
    Wong KM; Ding K; Li S; Bradbury P; Tsao MS; Der SD; Shepherd FA; Chung C; Ng R; Seymour L; Leighl NB
    Clin Lung Cancer; 2017 Jan; 18(1):e41-e47. PubMed ID: 27502323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong - A cost-effectiveness analysis.
    You JHS; Cho WCS; Ming WK; Li YC; Kwan CK; Au KH; Au JS
    PLoS One; 2021; 16(3):e0247860. PubMed ID: 33647045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature.
    Grossi F; Aita M; Follador A; Defferrari C; Brianti A; Sinaccio G; Belvedere O
    Oncologist; 2007 Apr; 12(4):451-64. PubMed ID: 17470688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer.
    Pilkington G; Boland A; Brown T; Oyee J; Bagust A; Dickson R
    Thorax; 2015 Apr; 70(4):359-67. PubMed ID: 25661113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.